EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described. 1. A method for preparing a pharmaceutical composition , the method comprising: (a1) a therapeutically effective quantity of at least one compound selected from the group consisting of epinephrine, phenylephrine, EPI-Shugarcaine and tropicamide;', '(a2) at least one metal chelator;', '(a3) optionally, at least one anesthetic;', '(a4) optionally, at least one non-steroid anti-inflammatory drug; and', '(a5) a quantity of sterile water,, '(a) preparing an aqueous composition consisting ofwherein the composition is optionally free of sulfites and is free of preservatives; and(b) lyophilizing the aqueous composition,to obtain thereby the lyophilized pharmaceutical composition2. The method of claim 1 , wherein the lyophilizing of the aqueous composition is carried out in a single container or in a bicameral container.3. The method of claim 2 , wherein the lyophilizing of the aqueous composition is carried out in the bicameral container.4. The method of claim 1 , further comprising adding to the lyophilized composition a quantity of sterile water prior to the use thereof claim 1 ,to obtain thereby a re-constituted pharmaceutical composition.5. The method of claim 1 , wherein the method is carried out in a single container or in a bicameral container.6. The method of claim 5 , wherein the method is carried out in the single container selected from the group consisting of a vial and an infusion bottle that is usable in the phacoemulsification procedure.7. The method of claim 6 , wherein the method is carried out in the bicameral container comprising a first section and a second section separated by a partition.8. The method of claim 7 , further ...

Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof

Medical articles are described, comprising a lens and a pharmaceutical composition incorporated into the lens, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone) and at least one pharmaceutically acceptable excipient. Methods for fabricating the medical articles and using them are also described.

PHARMACEUTICAL FORMULATIONS FOR TREATING MALE SEXUAL DYSFUNCTIONS

Pharmaceutical compositions and methods for treating various male sexual dysfunction disorders, such as erectile dysfunction or Peyronie's disease, are described, the compositions comprising a combination of certain pharmaceutically active components (e.g., alprostadil, papaverine, phentolamine and pentoxifylline) and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them are also described. 2. The pharmaceutical composition of claim 1 , wherein the prostaglandin compound is selected from the group consisting of prostaglandin E1 claim 1 , prostaglandin E2 claim 1 , prostaglandin D2 claim 1 , prostaglandin F2 claim 1 , prostaglandin 12 and thromboxane.3. The pharmaceutical composition of claim 2 , wherein the prostaglandin compound is alprostadil.4. The pharmaceutical composition of claim 1 , wherein each of R claim 1 , Rand Ris independently selected from the group consisting of H claim 1 , a C-Calkyl and an acyl-substituted C-Calkyl.5. The pharmaceutical composition of claim 1 , wherein the nonspecific phosphodiesterase inhibitor is selected from the group consisting of pentoxifylline claim 1 , caffeine claim 1 , aminophylline claim 1 , enprofylline claim 1 , isbufylline claim 1 , theophylline claim 1 , theobromine and 3-isobutyl-1-methylxanthine.6. The pharmaceutical composition of claim 1 , wherein the nonspecific phosphodiesterase inhibitor is pentoxifylline. The pharmaceutical composition of claim 1 , wherein the antispasmodic compound is selected from the group consisting of papaverine and bis-papaverine.87. The pharmaceutical composition of claim claim 1 , wherein the antispasmodic compound is papaverine.9. The pharmaceutical composition of claim 1 , wherein the non-selective α-adrenergic blocker is selected from the group consisting of phentolamine claim 1 , phenoxybenzamine claim 1 , tolazoline and trazodone.10. The pharmaceutical composition of claim 9 , wherein the non-selective α-adrenergic blocker is phentolamine. ...

EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described. 128-. (canceled)29. A kit , comprising a bicameral container comprising a first section and a second section separated by a partition , wherein the first section is filled with a quantity of a lyophilized composition and the second section is filled with a quantity of sterilized water , wherein the lyophilized composition comprises(a) one or more of epinephrine, phenylephrine, EPI-Shugarcaine and tropicamide;(b) at least one metal chelator;(c) optionally, at least one anesthetic; and(d) optionally, at least one non-steroid anti-inflammatory drug.30. The kit of claim 29 , wherein epinephrine is in the form of epinephrine hydrochlo-ride.31. The kit of claim 29 , wherein the metal chelator is selected from the group consisting of ethylenediaminetetraacetic acid and pharmaceutically acceptable salts thereof.32. The kit of claim 31 , wherein the pharmaceutically acceptable salt of ethylenediaminetetraacetic acid is disodium edetate.33. The kit of claim 31 , further comprising an additive selected from the group consisting of acetylcysteine claim 31 , glutathione claim 31 , ascorbic acid claim 31 , vitamin E and a balanced salts solution.34. The kit of claim 29 , wherein the anesthetic is selected from the group consisting of lidocaine claim 29 , proparacaine claim 29 , procaine claim 29 , tetracaine and combinations thereof.35. The kit of claim 29 , wherein the non-steroid anti-inflammatory drug is selected from the group consisting of ketorolac claim 29 , ketoprofen claim 29 , flurbiprofen claim 29 , bromfenac claim 29 , diclofenac and combinations thereof.36. The kit of claim 29 , further optionally comprising a sulfite or preservative.37. The ...

METHOD AND APPARATUS FOR SELF-DOSING AND SELF-ADMINISTERING PHARMACEUTICAL COMPOSITIONS

A method for self-dosing and self-administering a pharmaceutical or a cosmetic composition is provided. The method utilizes a three-dimensional dispensing device configured for receiving the composition. The dispensing device includes a bottom element having an inner surface and an outer surface and two side elements integrated with the bottom element, each side element being set at an angle to the bottom element. 1. A method for self-dosing and self-administering a formulation comprising a pharmaceutical or a cosmetic composition , the method comprising: (1) a bottom element having an inner surface and an outer surface;', '(2) two side elements integrated with the bottom element, each side element being set at an angle to the bottom element, each side element having an inner surface and an outer surface; and', '(3) optionally two lip elements, each lip element being integrated with each of the two side elements,, '(a) providing a three-dimensional dispensing device configured for receiving the formulation, the dispensing device comprisingwherein the bottom element and the two side elements define an inner space contained therebetween, with the further provisos that:the bottom element together with the two side elements comprise a central area for receiving the formulation,the dispensing device is capable of being flattened by pressuring the bottom element, the two side elements and optionally the lip element into a two-dimensional shape;(b) dispensing the required amount of the formulation onto the central area of the dispensing device;(c) unfolding the dispensing device into the two-dimensional shape; and(d) transferring the formulation from the dispensing device to the area of the user's body that is in need of treatment,to self-dose and self-administer the formulation thereby.2. The method of claim 1 , wherein the formulation is selected from the group consisting of pharmaceutically acceptable or cosmetically useful creams claim 1 , pastes claim 1 , ointments ...

INTRAOCULAR LENS COMPRISING PHARMACEUTICAL COMPOSITIONS AND METHODS FOR FABRICATING THEREOF

Medical article are described, comprising a lens and a pharmaceutical composition incorporated into the lens, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone) and at least one pharmaceutically acceptable excipient. Methods for fabricating the medical articles and using them are also described. 1. A medical article of manufacture , comprising:(a) a lens selected from the group consisting of an intraocular lens and a contact lens that is originally free of pharmaceutically active compounds; and (b1) a dispersed phase that includes solid particles; and', '(b2) a dispersion medium comprising a pharmaceutically acceptable carrier and at least one pharmaceutically acceptable solubilizing and suspending agent selected from the group consisting of non-ionic polyoxyethlene-polyoxypropylene block copolymers,', 'with the further provisos that the solid particles in the dispersed phase comprise:', '(1) a therapeutically effective quantity of an anti-bacterial agent independently selected from the group consisting of quinolone, a fluorinated quinolone and pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof; and', '(2) a therapeutically effective quantity of an anti-inflammatory agent independently selected from the group consisting of corticosteroids and pharmaceutically acceptable salts, hydrates, solvates, ethers, esters, acetals and ketals thereof., '(b) a pharmaceutical composition incorporated into the lens, wherein the pharmaceutical composition is a suspension comprising2. The medical article of claim 1 , wherein the anti-bacterial agent is a fluorinated quinolone.3. The medical article of claim 2 , wherein the fluorinated quinolone is selected from the group consisting of moxifloxacin and gatifloxacin.4. The medical article of claim 3 , wherein the fluorinated quinolone is ...

EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described. 1. A method for preparing a pharmaceutical composition , the method comprising: (a1) a therapeutically effective quantity of at least one compound selected from the group consisting of epinephrine, phenylephrine, EPI-Shugarcaine and tropicamide;', '(a2) at least one metal chelator;', '(a3) optionally, at least one anesthetic;', '(a4) optionally, at least one non-steroid anti-inflammatory drug; and', '(a5) a quantity of sterile water,, '(a) preparing an aqueous composition consisting ofwherein the composition is optionally free of sulfites and is free of preservatives; and(b) lyophilizing the aqueous composition,to obtain thereby the lyophilized pharmaceutical composition2. The method of claim 1 , wherein the lyophilizing of the aqueous composition is carried out in a single container or in a bicameral container.3. The method of claim 2 , wherein the lyophilizing of the aqueous composition is carried out in the bicameral container.4. The method of claim 1 , further comprising adding to the lyophilized composition a quantity of sterile water prior to the use thereof claim 1 ,to obtain thereby a re-constituted pharmaceutical composition.5. The method of claim 1 , wherein the method is carried out in a single container or in a bicameral container.6. The method of claim 5 , wherein the method is carried out in the single container selected from the group consisting of a vial and an infusion bottle that is usable in the phacoemulsification procedure.7. The method of claim 6 , wherein the method is carried out in the bicameral container comprising a first section and a second section separated by a partition.8. The method of claim 7 , further ...

METHODS AND SYSTEM FOR MEASURING INTERACTION BETWEEN A USER INTERFACE AND REMOTE SERVER

Some embodiments of the present disclosure present methods and systems for measuring an interaction level between a user interface and a remote server and charges for the interaction. In some embodiments, a connection may be established between a user device accessing a piece of content and a remote server configured to communicate with the user device interactively about a piece of content pertaining to a second server. In some cases, the communication between the second server and the user device can be in response to an indication of interest in the piece of content from a user of the user device. In some embodiments, the second server may measure the level of interaction between the user via the user device and the second server, and report the measure to the first server. A health application may include measuring interactions between a host website, user device, care provider device, pharmacy device, and service coordinator. 1. A method , comprising:establishing, by a processor of a first server, a connection linking the first server to a user interface hosting a piece of content and associated with a second server;receiving, at the second server, an indication of interest in the piece of content from the user interface;communicating with the user interface, via the connection and by the second server, in response to the indication of interest from the user interface;tracking, via the processor of the second server, a measure of interaction between the user interface and the second server; andreporting, to the second server and/or a service provider of the first server, the measure of interaction between the user interface and the second server.2. The method of claim 1 , wherein:the piece of content is an advertisement for an ophthalmological service, andthe communicating with the user interface includes communicating an inquiry to the user interface about an ophthalmological need based on the indication of interest.3. The method of claim 1 , wherein the ...

EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described. 1. A pharmaceutical composition comprising: (a1) an active component comprising a therapeutically effective quantity of at least one compound selected from the group consisting of epinephrine, phenylephrine, EPI-Sugarcaine and tropicamide;', '(a2) at least one metal chelator;', '(a3) optionally, at least one anesthetic; and', '(a4) optionally, at least one non-steroid anti-inflammatory drug; and, '(a) a therapeutic element comprising(b) a pharmaceutically acceptable aqueous carrier therefor,wherein the therapeutic element is fully lyophilized or optionally comprises a lyophilized portion and a non-lyophilized portion,with the further proviso that the composition is optionally free of sulfites and is optionally free of preservatives.2. The pharmaceutical composition of claim 1 , wherein the therapeutic element is fully lyophilized.3. The pharmaceutical composition of claim 1 , wherein epinephrine is in the form of epinephrine hydrochloride.4. The pharmaceutical composition of claim 1 , wherein the metal chelator is selected from the group consisting of ethylenediaminetetraacetic acid and pharmaceutically acceptable salts thereof.5. The pharmaceutical composition of claim 4 , wherein the pharmaceutically acceptable salt of ethylenediaminetetraacetic acid is disodium edetate.6. The pharmaceutical composition of claim 4 , further comprising an additive selected from the group consisting of acetylcysteine claim 4 , glutathione claim 4 , ascorbic acid claim 4 , vitamin E and a balanced salts solution.7. The pharmaceutical composition of claim 1 , wherein the anesthetic is selected from the group consisting of lidocaine claim 1 , proparacaine claim ...

PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF

Pharmaceutical compositions for intraocular administration are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as triamcinolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular administration are also described as well as pharmaceutical kits designed for administering the compositions. 1. A pharmaceutical kit , comprising: [ (a1) a therapeutically effective quantity of an anti-bacterial agent independently selected from the group consisting of a quinolone, a fluorinated quinolone and a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof; and', '(a2) a therapeutically effective quantity of an anti-inflammatory agent independently selected from the group consisting of a corticosteroid and a pharmaceutically acceptable salt, hydrate, solvate, ether, ester, acetal and ketal thereof;, '(a) a therapeutic component consisting essentially of, '(b) optionally, at least one pharmaceutically acceptable excipient suitable for intraocular administration; and', '(c) optionally, a pharmaceutically acceptable carrier therefor suitable for intraocular administration;, '(1) a sealed container containing an ophthalmic pharmaceutical composition comprising(2) one or several drug delivery devices for administering the pharmaceutical composition; and(3) an instruction for the use of the composition.2. The kit of claim 1 , wherein the drug delivery device is selected from the group consisting of devices for delivery by injection claim 1 , devices for delivery via eye drops and devices for delivery via spray.3. The kit of claim 2 , wherein the drug delivery device is a device for delivery by injection selected from the group consisting of a needle and a cannula.4. The kit of claim 3 , ...

Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof

Pharmaceutical compositions for treating, mitigating or preventing autoimmune diseases and associated conditions are described herein. Methods for fabricating the compositions and using them are also described.

PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF

Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as triamcinolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular injections are also described. 1. An ophthalmological pharmaceutical composition , comprising: (a1) a therapeutically effective quantity of an anti-inflammatory agent independently selected from the group consisting of corticosteroids and pharmaceutically acceptable salts, hydrates, solvates, ethers, esters, acetals and ketals thereof; and', '(a2) a therapeutically effective quantity of non-steroid anti-inflammatory drug that is free of bromfenac;, '(a) a therapeutic component consisting essentially of(b) optionally, at least one pharmaceutically acceptable excipient; and(c) optionally, a pharmaceutically acceptable carrier therefor.2. The pharmaceutical composition of claim 1 , wherein the therapeutic component further comprises a therapeutically effective quantity of a primary anti-bacterial agent independently selected from the group consisting of quinolone claim 1 , a fluorinated quinolone and pharmaceutically acceptable salts claim 1 , hydrates claim 1 , solvates or N-oxides thereof.3. The pharmaceutical composition of claim 2 , wherein the primary anti-bacterial agent is a fluorinated quinolone.4. The pharmaceutical composition of claim 3 , wherein the fluorinated quinolone is selected from the group consisting of moxifloxacin and gatifloxacin.5. The pharmaceutical composition of claim 4 , wherein the fluorinated quinolone is moxifloxacin.7. The pharmaceutical composition of claim 1 , wherein the corticosteroid is selected from the group consisting of triamcinolone claim 1 , triamcinolone acetonide claim 1 , ...

Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof

Pharmaceutical compositions for treating, mitigating or preventing autoimmune diseases and associated conditions are described herein. Methods for fabricating the compositions and using them are also described.

Pharmaceutical formulations for treating glaucoma and methods for fabricating and using thereof

Pharmaceutical compositions for treating or mitigating glaucoma are described, the compositions comprising several separate components for an improved effect. Methods for fabricating the compositions and using them are also described.

ADRENOCORTICOTROPIC HORMONE-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR FABRICATING AND USING THEREOF

Pharmaceutical compositions for treating, mitigating or preventing multiple sclerosis, autoimmune diseases and associated conditions are described herein. Methods for fabricating the compositions and using them are also described. 1. A pharmaceutical composition , comprising a quantity corticotropin of a non-animal derivation , wherein the composition is free of gelatin and free of preservatives.2. The pharmaceutical composition of claim 1 , wherein the corticotropin comprises a quantity of a recombinant polypeptide and optionally a quantity of a naturally occurring polypeptide.3. The pharmaceutical composition of claim 2 , wherein the corticotropin is free of the naturally occurring polypeptide.4. The pharmaceutical composition of claim 3 , wherein the recombinant polypeptide is the amino acid sequence selected from the group of SEQ ID NO: 1 claim 3 , SEQ ID NO: 2 claim 3 , SEQ ID NO: 3 claim 3 , SEQ ID NO: 4 claim 3 , SEQ ID NO: 5 claim 3 , and combinations thereof.5. The pharmaceutical composition of claim 4 , wherein the recombinant polypeptide is the amino acid sequence as set forth in SEQ ID NO: 1.6. The pharmaceutical composition of claim 1 , further comprising an amino acid selected from the group consisting of cysteine claim 1 , methionine claim 1 , and combinations thereof.7. The pharmaceutical composition of claim 6 , further comprising a water-soluble thickening agent selected from the group consisting of carboxymethyl cellulose claim 6 , dextrose claim 6 , mannitol claim 6 , methyl cellulose claim 6 , hydroxyethyl cellulose claim 6 , hydroxypropyl cellulose claim 6 , non-cross-linked or partially cross-linked polyacrylates claim 6 , polyoxyethylene sorbitan monolaurates claim 6 , polyoxyethylene sorbitan monopalmitates claim 6 , polyoxyethylene sorbitan monostearates claim 6 , polyoxyethylene sorbitan monooleates claim 6 , and combinations thereof.8. The pharmaceutical composition of claim 7 , further comprising at least one non-ionic poly(oxyethlene-co ...

Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof

Medical articles are described, comprising a lens and a pharmaceutical composition incorporated into the lens, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone) and at least one pharmaceutically acceptable excipient. Methods for fabricating the medical articles and using them are also described.

PHARMACEUTICAL FORMULATIONS OF XANTHINE OR XANTHINE DERIVATIVES

Pharmaceutical compositions and methods for treating various diseases and pathologies, such as Dupuytren contracture, are described, the compositions comprising pentoxifylline and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them are also described. 2. The method of claim 1 , wherein each of R claim 1 , Rand Ris independently selected from the group consisting of H and an optionally substituted C-Calkyl.3. The method of claim 1 , wherein each of R claim 1 , Rand Ris independently selected from the group consisting of H claim 1 , a C-Calkyl and an acyl-substituted C-Calkyl.4. The method of claim 1 , wherein the compound of formula I is a nonspecific phosphodiesterase inhibitor.5. The method of claim 4 , wherein the nonspecific phosphodiesterase inhibitor is selected from the group consisting of pentoxifylline claim 4 , caffeine claim 4 , aminophylline claim 4 , enprofylline claim 4 , isbufylline claim 4 , theophylline claim 4 , theobromine and 3-isobutyl-1-methylxanthine.6. The method of claim 4 , wherein the nonspecific phosphodiesterase inhibitor is pentoxifylline.8. The method of claim 7 , wherein each of R claim 7 , Rand Ris independently selected from the group consisting of H and an optionally substituted C-Calkyl.9. The method of claim 7 , wherein each of R claim 7 , Rand Ris independently selected from the group consisting of H claim 7 , a C-Calkyl and an acyl-substituted C-Calkyl.10. The method of claim 7 , wherein the compound of formula I is a nonspecific phosphodiesterase inhibitor.11. The method of claim 10 , wherein the nonspecific phosphodiesterase inhibitor is selected from the group consisting of pentoxifylline claim 10 , caffeine claim 10 , aminophylline claim 10 , enprofylline claim 10 , isbufylline claim 10 , theophylline claim 10 , theobromine and 3-isobutyl-1-methylxanthine.12. The method of claim 11 , wherein the nonspecific phosphodiesterase inhibitor is pentoxifylline.13. The method of claim 1 , ...

EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described. 2. The method of claim 1 , wherein the epinephrine is in the form of epinephrine hydrochloride.3. The method of claim 1 , wherein the pharmaceutically acceptable salt of ethylenediaminetetraacetic acid is disodium edetate.4. The method of claim 1 , wherein the at least one anesthetic is selected from the group consisting of lidocaine claim 1 , proparacaine claim 1 , procaine claim 1 , tetracaine claim 1 , and combinations thereof.5. The method of claim 1 , wherein the at least one non-steroid anti-inflammatory drug is selected from the group consisting of ketorolac claim 1 , ketoprofen claim 1 , flurbiprofen claim 1 , bromfenac claim 1 , diclofenac and combinations thereof.6. The method of claim 1 , wherein the ophthalmic pharmaceutical composition consists of tropicamide claim 1 , phenylephrine HCl claim 1 , ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof claim 1 , lidocaine HCl claim 1 , sodium chloride claim 1 , hydrochloric acid claim 1 , and/or sodium hydroxide claim 1 , and sodium diclofenac in sterile water. This application is a continuation of U.S. application Ser. No. 15/247,524 filed on Aug. 25, 2016 entitled “Epinephrine Compositions for Intraocular Administration and Methods for Fabricating Thereof” which is a continuation-part-application of U.S. application Ser. No. 14/506,120 filed on Oct. 3, 2014 entitled “Epinephrine-Based Compositions and Methods for Fabricating Thereof,” the entire contents of which is hereby incorporated by reference, and to which it claims priority under 35 U.S.C. § 120, and which claims priority under 35 U.S.C. § 119(e) to each of the following U.S. Provisional ...

EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described. 1. A method of rapidly dilating a subject's pupils , the method comprising: a therapeutically effective quantity of at least one compound selected from the group consisting of phenylephrine hydrochloride and tropicamide;', 'at least one metal chelator;', 'optionally, at least one anesthetic;', 'optionally, at least one tonicity adjusting agent comprising one or more chloride salts selected from the group consisting of sodium chloride, potassium chloride, and magnesium chloride;', 'optionally, hydrochloric acid and/or sodium hydroxide;', 'optionally, at least one non-steroid anti-inflammatory drug;', 'optionally, at least one excipient; and', 'a quantity of sterile water,, 'administering to the subject a therapeutically effective amount of a composition consisting ofwherein the subject's pupils are dilated within one minute or less after administering the composition.2. The method of wherein the subject's pupils have a first diameter before the administration of the composition and a second diameter after the administration of the composition.3. The method of wherein the first diameter is at least about 1.0 mm.4. The method of wherein the second diameter is at least about 6.0 mm.5. The method of wherein the subject's pupils are dilated within 40 seconds or less after administering the composition.6. The method of wherein the subject's pupils are dilated within 30 seconds or less after administering the composition.7. The method of claim 1 , wherein the at least one metal chelator is ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof.8. The method of claim 1 , wherein the at least one non-steorid anti-inflammatory ...

SYSTEMS AND METHODS FOR AUTOMATED INTAKE OF PATIENT DATA

Some embodiments of the present disclosure disclose methods and systems for automated intake of patient data, and more specifically, for generating structured database of patients and real-time identification of health care providers for the patients based on the received real-time patient data. A patient intake server may receive from a patient intake device, a patient intake data including unstructured patient intake data related to personal or medical information of the patient. The patient intake server may select an engine configured to process the unstructured patient intake data to convert the unstructured patient intake data into a structured patient intake data. In some embodiments, the patient intake server may identify one or more health care providers qualified to provide the medical care to the patient based on an analysis of the structured patient intake data. 1. A method , comprising:receiving, at a processor and from a patient intake device, a patient intake data including unstructured patient intake data related to personal or medical information of the patient;selecting, via the processor, an engine configured to process the unstructured patient intake data;processing, by the processor and using the engine, the unstructured patient intake data to convert the unstructured patient intake data into a structured patient intake data; andidentifying, via the processor, one or more health care providers qualified to provide the medical care to the patient based on an analysis of the structured patient intake data.2. The method of claim 1 , wherein the unstructured patient intake data is voice data of the patient including the personal or medical information of the patient.3. The method of claim 2 , wherein the engine configured to process the voice data is a voice recognition engine configured to extract the personal or medical information of the patient from the voice data.4. The method of claim 2 , further comprising identifying an identity of the ...

Systems and methods for transacting prescriptions using a mobile device

Some embodiments of the present disclosure disclose methods and systems for issuing and filling medical prescriptions for a patient. In some embodiments, the system may include a mobile device for use by the medical prescriber in cellular communication with a computer network that in turn is coupled to a computer server. The computer server may include an authentication engine configured to authenticate the identity of a prescriber of a medication, medical device, medical treatment, etc., and a prescription engine configured to generate a prescription based on a message from the mobile device that may be in the form of an image, audio file, text message, etc., based on the result of the authentication.

Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof

Pharmaceutical compositions for treating, mitigating or preventing multiple sclerosis, autoimmune diseases and associated conditions are described herein. Methods for fabricating the compositions and using them are also described.

epinephrine-based ophthalmic compositions for intraocular administration and methods for making same

resumo composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas composições farmacêuticas para injeção intraocular são descritas, as com-posições compreendem uma quantidade terapeuticamente eficaz de epinefrina ou adrenalina livre de conservante e livre de sulfito liofilizada e um quelante de metal. métodos para fabricar as composições e usar as mesmas para injeções intraocula-res também são descritos. Summary Epinephrine-based ophthalmic compositions for intraocular administration and methods for manufacturing the same intraocular injection pharmaceutical compositions are described, the compositions comprising a therapeutically effective amount of lyophilized sulfide free preservative-free epinephrine or adrenaline and a metal chelator. Methods for making the compositions and using them for intraocular injections are also described.

Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.

Aligning cells on wrinkled surface

A method is provided for preparing a tissue patch comprising the steps of placing one or more cells on a surface having a texture, which texture has an average height of from about 100 nanometers to about 5 micrometers; allowing the cells to migrate or divide on the surface; and removing the cell population from the textured surface, thereby forming tissue patch. Also provided a method to prepare the surface which method comprises the steps of: a) depositing a metal onto a pre-stressed thermoplastic material; b) reducing the surface area of the receptive material by at least about 60%; and c) preparing the surface via lithography.

Antibacterial compositions and methods for fabricating thereof

Pharmaceutical compositions are described, the compositions comprising a therapeutically effective quantity of at least one glycopeptide antibiotic, at least one aminoglycoside antibiotic, and at least one amino acid. Methods for fabricating the compositions and using them are also described.

Extended-release pharmaceutical compositions for treating eye conditions

The present disclosure encompasses methods and compositions for extended-release formulations for treating ophthalmic conditions. These formulations comprise a pharmaceutical agent, a cationic polymer, a non-ionic polymer, and a pharmaceutical carrier and are essentially preservative free. The formulations provided herein are particularly useful for sustained and controlled release of drugs and have low side effects.

Systems and methods for automated intake of patient data

Some embodiments of the present disclosure disclose methods and systems for automated intake of patient data, and more specifically, for generating structured database of patients and real-time identification of health care providers for the patients based on the received real-time patient data. A patient intake server may receive from a patient intake device, a patient intake data including unstructured patient intake data related to personal or medical information of the patient. The patient intake server may select an engine configured to process the unstructured patient intake data to convert the unstructured patient intake data into a structured patient intake data. In some embodiments, the patient intake server may identify one or more health care providers qualified to provide the medical care to the patient based on an analysis of the structured patient intake data.

Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof

Pharmaceutical compositions for treating, mitigating or preventing autoimmune diseases and associated conditions are described herein. Methods for fabricating the compositions and using them are also described.

Pharmaceutical formulations for treating glaucoma and methods for fabricating and using thereof

Pharmaceutical compositions for treating or mitigating glaucoma are described, the compositions comprising several separate components for an improved effect. Methods for fabricating the compositions and using them are also described.

Pharmaceutical formulations for treating glaucoma and methods for fabricating and using thereof

Methods and system for remotely capturing media via a user interface bidirectionally linked to a remote server

Some embodiments of the present disclosure present methods and systems for remotely capturing an image of an eye of a user via a user interface bidirectionally linked to a remote server that is configured to anonymize data communicated from the user device. In some embodiments, a user device may activate its camera after receiving a request at the user interface from the remote server. Further, the user interface may determine a zoom level for the camera to capture the image of the eye of the user facing the camera and capture the image based on the determined zoom level. In some instances, the user device may transmit the data including the captured image to the remote server via an encrypted bi-directional communication link.

Extended-release pharmaceutical compositions for treating eye conditions

The present disclosure encompasses methods and compositions for extended-release formulations for treating ophthalmic conditions. These formulations comprise a pharmaceutical agent, a cationic polymer, a non-ionic polymer, and a pharmaceutical carrier and are essentially preservative free. The formulations provided herein are particularly useful for sustained and controlled release of drugs and have low side effects.

Extended-release pharmaceutical compositions for treating eye conditions

The present disclosure encompasses methods and compositions for extended-release formulations for treating ophthalmic conditions. These formulations comprise a pharmaceutical agent, a cationic polymer, a non-ionic polymer, and a pharmaceutical carrier and are essentially preservative free. The formulations provided herein are particularly useful for sustained and controlled release of drugs and have low side effects.